{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13(1)"],"submitter":["Velut Y"],"pubmed_abstract":["The standard of care for the follow-up of kidney allograft recipients combines non-invasive but non-specific biomarkers and kidney biopsies for the gold standard histology-based diagnosis, limited by the sampling bias, haemorrhagic risk, and low cost-effectiveness. We hypothesized that a targeted epigenetic analysis of cell-free DNA (cfDNA) would combine non-invasiveness and specificity for the diagnosis of kidney allograft rejection. We developed an in silico pipeline to identify 9 specific methylation signatures of epithelial or endothelial cell types in glomerular and tubular kidney compartments. Methylation-specific digital Polymerase Chain Reaction (dPCR) were designed and validated for these markers and combined in a 10-plex dPCR. In a retrospective cohort of 170 plasma cfDNA from ad"],"journal":["Biomarker research"],"pagination":["118"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12465476"],"repository":["biostudies-literature"],"pubmed_title":["Epigenetic signatures on plasma cell-free DNA to detect kidney allograft rejection in a non-invasive way: development of a 10-plex digital PCR assay."],"pmcid":["PMC12465476"],"pubmed_authors":["Heneine J","Choukroun G","Bersez T","Rabant M","Ferlicot S","Anglicheau D","Snanoudj R","Vuiblet V","Gnanalingam S","Verkarre V","de Nattes T","Parier B","Buob D","Velut Y","Maujean C","Boyer P","Poulet G","Moniot C","Galichon P","Audenet F"],"additional_accession":[]},"is_claimable":false,"name":"Epigenetic signatures on plasma cell-free DNA to detect kidney allograft rejection in a non-invasive way: development of a 10-plex digital PCR assay.","description":"The standard of care for the follow-up of kidney allograft recipients combines non-invasive but non-specific biomarkers and kidney biopsies for the gold standard histology-based diagnosis, limited by the sampling bias, haemorrhagic risk, and low cost-effectiveness. We hypothesized that a targeted epigenetic analysis of cell-free DNA (cfDNA) would combine non-invasiveness and specificity for the diagnosis of kidney allograft rejection. We developed an in silico pipeline to identify 9 specific methylation signatures of epithelial or endothelial cell types in glomerular and tubular kidney compartments. Methylation-specific digital Polymerase Chain Reaction (dPCR) were designed and validated for these markers and combined in a 10-plex dPCR. In a retrospective cohort of 170 plasma cfDNA from ad","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-07-15T06:48:48.996Z","creation":"2026-06-30T03:23:39.082Z"},"accession":"S-EPMC12465476","cross_references":{"pubmed":["41013855"],"doi":["10.1186/s40364-025-00834-7"]}}